Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 14/20 | 0.68 |
| ▸ | GLP1R | P43220 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193571 | 0.98 | GRPR (0.67) | GRPRGLP1ROPRM1OPRD1 | |
| SCHEMBL29663974 | 0.97 | GRPR (0.68) | GRPRGLP1ROPRM1OPRD1 | |
| SCHEMBL31069834 | 0.95 | GRPR (0.66) | GRPRGLP1R | |
| SCHEMBL30118089 | 0.94 | GRPR (0.65) | GRPRGLP1ROPRM1OPRD1 | |
| SCHEMBL38661265 | 0.93 | GRPR (0.65) | GRPRGLP1ROPRM1OPRD1 | |
| SCHEMBL30118082 | 0.92 | GRPR (0.65) | GRPRGLP1R | |
| SCHEMBL7237024 | 0.92 | GRPR (0.74) | GRPR | |
| SCHEMBL29484954 | 0.92 | GRPR (0.67) | GRPRGLP1R | |
| SCHEMBL29484960 | 0.92 | GRPR (0.67) | GRPRGLP1R | |
| SCHEMBL30816315 | 0.92 | GRPR (0.63) | GRPRGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026827-A1 | Octapeptide bombesin analogs | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS, A PARIS, FRANCE | 2005-02-03 | — | — | US | claimed |
| US-20030050436-A1 | Octapeptide bombesin analogs | BIOMEASURE INC., MASSACHUSETTS CORPORATION | 2003-03-13 | — | — | US | claimed |
| US-6307017-B1 | Octapeptide bombesin analogs | BIOMEASURE, INCORPORATED | 2001-10-23 | — | — | US | claimed |
| US-5217955-A | Treating colon, prostate or breast cancer in mammals | BIOMEASURE, INC. (US) | 1993-06-08 | — | — | US | claimed |
| EP-0448677-A4 | TREATMENT OF COLON CANCER | — | 1992-08-26 | — | — | EP | claimed |
| EP-0438519-A4 | THERAPEUTIC PEPTIDES | UNIV TULANE (US) | 1991-10-30 | — | — | EP | claimed |
| EP-0448677-A1 | TREATMENT OF COLON CANCER | BIOMEASURE, INC. (US) | 1991-10-02 | — | — | EP | claimed |
| EP-0438519-A1 | THERAPEUTIC PEPTIDES | The Administrators of The Tulane Educational Fund (US) | 1991-07-31 | — | — | EP | claimed |
| WO-1991004040-A1 | TREATMENT OF COLON CANCER | BIOMEASURE, INC. (US) | 1991-04-04 | — | — | WO | claimed |
| WO-1990003980-A1 | THERAPEUTIC PEPTIDES | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1990-04-19 | — | — | WO | claimed |
| US-20050026827-A1 | Octapeptide bombesin analogs | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS, A PARIS, FRANCE | 2005-02-03 | — | — | US | disclosed |
| US-20030050436-A1 | Octapeptide bombesin analogs | BIOMEASURE INC., MASSACHUSETTS CORPORATION | 2003-03-13 | — | — | US | disclosed |
| US-6307017-B1 | Octapeptide bombesin analogs | BIOMEASURE, INCORPORATED | 2001-10-23 | — | — | US | disclosed |
| US-5877277-A | ANTIPROLIFERATIVE/ANTICARCINOGENIC/ANTITUMOR AGENTS WITH MODIFIED AMINO ACIDS FOR COMPETITIVE INHIBITION OF NATURALLY OCCURING PEPTIDE BY BINDING TO RECEPTORS; TREATMENT OF GASTROINTESTINAL DISORDERS | BIOMEASURE, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| US-5736517-A | ADMINISTERING TO TREAT COLON, PROSTATE OR BREAST CANCER | BIOMEASURE, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0448677-A1 | TREATMENT OF COLON CANCER | BIOMEASURE, INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| EP-0438519-A1 | THERAPEUTIC PEPTIDES | The Administrators of The Tulane Educational Fund (US) | 1991-07-31 | — | — | EP | disclosed |
| WO-1991004040-A1 | TREATMENT OF COLON CANCER | BIOMEASURE, INC. (US) | 1991-04-04 | — | — | WO | disclosed |
| WO-1991002746-A1 | THERAPEUTIC PEPTIDES | BIOMEASURE, INC. (US) | 1991-03-07 | — | — | WO | disclosed |
| WO-1990003980-A1 | THERAPEUTIC PEPTIDES | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1990-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050436-A1 | Octapeptide bombesin analogs | GRPR, GHRHR, VGF | GRPR 1/4885GLP1R 43/4885OPRM1 824/4885 |
| US-20050026827-A1 | Octapeptide bombesin analogs | GRPR, VGF, GHRHR | GRPR 1/4885GLP1R 26/4885OPRM1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.